Anaplastic astrocytoma in adults.

Détails

ID Serval
serval:BIB_14684230FF80
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Anaplastic astrocytoma in adults.
Périodique
Critical reviews in Oncology/Hematology
Auteur(s)
Stupp R., Reni M., Gatta G., Mazza E., Vecht C.
ISSN
1040-8428
Statut éditorial
Publié
Date de publication
2007
Peer-reviewed
Oui
Volume
63
Numéro
1
Pages
72-80
Langue
anglais
Notes
Publication types: Comparative Study ; Journal Article ; Review
Résumé
Anaplastic astrocytoma is an uncommon disease in the adult population. Prognosis is influenced by age, symptom duration, mental status and Karnofsky performance status. A truly complete resection, which is a recognized independent prognostic factor, is not possible and recurrence in the surgical cavity is common. Based on randomized data available, chemotherapy has consistently failed to improve the outcome of patients with anaplastic astrocytoma, while a meta-analysis showed a small, but significant improvement in survival favouring the use of chemotherapy. Outside a clinical trial, postoperative radiotherapy (30 x 2 Gy) remains the standard adjuvant therapy for most patients. For elderly patients, the application of treatment is usually based on performance status and neurological function. In recurrent disease, chemotherapy with temozolomide has been proven to be active and well-tolerated in phase II trials, but no comparative phase III trials of other cytotoxic drugs have been conducted.
Mots-clé
Adolescent, Adult, Aged, Antineoplastic Agents, Alkylating, Astrocytoma, Brain Neoplasms, Clinical Trials as Topic, Clinical Trials, Phase II as Topic, Dacarbazine, Female, Humans, Incidence, Male, Middle Aged, Neoplasm Recurrence, Local, Prognosis, Risk Factors, Survival Analysis
Pubmed
Web of science
Création de la notice
28/01/2008 9:39
Dernière modification de la notice
20/08/2019 13:43
Données d'usage